Meeting
2021 ASCO Annual Meeting
Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy.
Authors
Umair Majeed
Mayo Clinic, Jacksonville, FL
Umair Majeed , Pedro Luiz Serrano Uson Junior , Jun Yin , Mohamad Bassam Sonbol , Daniel H. Ahn , Tanios S. Bekaii-Saab , Jason S. Starr , Jeremy C Jones , Samantha R Inabinett , Natasha Wylie , Ashton WR Boyle , Mitesh J. Borad , Kabir Mody
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4079)
DOI
10.1200/JCO.2021.39.15_suppl.4079
Abstract #
4079
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
First Author: Maeve Aine Lowery
Poster
2014 ASCO Annual Meeting
Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.
First Author: Bertrand Brieau
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world assessment of treatment sequencing of patients with advanced biliary tract cancer in a private practice in Rio de Janeiro and São Paulo, Brazil.
First Author: Ligia Carvalho